Zou Daoyang, Xin Xi, Xu Yunxian, Xu Huangzhen, Huang Linyan, Xu Tianwen
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Ganzhou People's Hospital, Ganzhou, 341000, China.
Heliyon. 2024 Aug 16;10(16):e36446. doi: 10.1016/j.heliyon.2024.e36446. eCollection 2024 Aug 30.
Currently, immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for many malignant tumors. As the most common digestive tract malignancy, colorectal cancer (CRC) shows a good response to ICIs only in a small subset of patients with MSI-H/dMMR CRC. In contrast, patients with MSS/pMMR CRC show minimal response to ICIs. The results of the REGONIVO study suggest that targeting the tumor microenvironment (TME) to improve immunotherapy outcomes in MSS/pMMR CRC patients is a feasible strategy. Therefore, this article focuses on exploring the feasibility of targeting the TME to enhance immunotherapy outcomes in CRC, collecting recent basic research on targeting the TME to enhance immunotherapy outcomes in CRC and analyzing ongoing clinical trials to provide a theoretical basis and future research directions for improving immunotherapy outcomes in MSS/pMMR CRC.
目前，免疫检查点抑制剂（ICIs）已经改变了许多恶性肿瘤的治疗模式。作为最常见的消化道恶性肿瘤，结直肠癌（CRC）仅在一小部分微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）的CRC患者中对ICIs表现出良好反应。相比之下，微卫星稳定/错配修复功能正常（MSS/pMMR）的CRC患者对ICIs的反应极小。REGONIVO研究结果表明，针对肿瘤微环境（TME）以改善MSS/pMMR CRC患者的免疫治疗效果是一种可行的策略。因此，本文着重探讨针对TME增强CRC免疫治疗效果的可行性，收集近期关于针对TME增强CRC免疫治疗效果的基础研究，并分析正在进行的临床试验，以为改善MSS/pMMR CRC的免疫治疗效果提供理论依据和未来研究方向。
